The combination of nivolumab and ipilimumab may be more effective for treating metastatic renal cell carcinoma (mRCC) than monotherapy with either agent, researchers have reported (J Clin Oncol 2017 Jul 5. [Epub ahead of print]). The results of their Phase II, open-label study found an overall survival rate of nearly 70% at two years with the combination.
“These results support the safety of nivolumab plus ipilimumab combination therapy in mRCC … [and provide] preliminary support